Background 25
BRCA1/BRCA2 genes were discovered in early 1990s and clinical testing for these has been 26 available since the mid-1990s. National Institute of Health and Care Excellence (NICE) and other 27 international guidelines recommend genetic-testing at a ~10% probability threshold of carrying a 28 BRCA-mutation. A detailed three generation family-history (FH) of cancer is used within complex 29 mathematical models (e.g. BOADICEA, BRCAPRO, Manchester-Scoring-System) or through 30 standardized clinical-criteria to identify individuals who fulfil this probability threshold and can be 31 offered genetic-testing. Identification of unaffected carriers is important given the high risk of 32 cancer in these women and the effective options available for clinical management which can 33 reduce cancer risk, improve outcomes and minimise burden of disease. Risk-reducing salpingo-34 oophorectomy (RRSO) once the family is complete is the most effective option to reduce ovarian 35 cancer (OC) risk. Taking the combined contraceptive-pill can reduce OC-risk by half. Risk-reducing 36 mastectomy (RRM) is the most effective option for reducing breast cancer (BC) risk. Additionally 37 high-risk women can opt for chemoprevention with selective estrogen-receptor-modulators 38 (SERM) as well as early-onset annual MRI/mammography screening. Carrier identification also 39 offers the opportunity for making informed reproductive and contraceptive choices affecting 40 cancer risk, including timing of having children, pill-use, and pre-implantation genetic-diagnosis 41 (PGD). In women affected by cancer it offers the choice of targeted therapy using drugs like PARP-42 inhibitors to improve survival as well as access to novel clinical trials. Additionally unaffected 43 family members can be identified through cascade-testing and offered options of 44 screening/prevention. 45
This clinical-criteria/FH based approach has numerous limitations. While moderately effective at 46 identifying individuals with mutations, it is poor at ruling out the presence of one. We 1 and others 2, 47 approach. Data suggest that over 80% patients fulfilling clinical-criteria for genetic-testing have 50 never discussed this with a health-professional. Another drawback is the need for an individual in 51 a family to develop cancer before others who are unaffected can be identified. Why should we 52 need to wait for this to happen? Despite over two decades of testing, only 3% of estimated carriers 53 in the population have been identified. 4 Limited public and health professional awareness, 54 coupled with the complexity and inefficiencies of a gate keeper driven testing pathway/service 55 structure has resulted in restricted access and under-utilisation of genetic-testing across all health 56 systems.
5 Continuing at the current rates of identification, we will never identify even the 50% of 57 the estimated residual pool of carriers in the population who fulfil testing criteria, let alone the 58 unidentifiable half. Even doubling current rates will warrant ~165 years to identify these 50% at-59 risk individuals. 4 Incorporation of mainstreaming into clinical practice will improve detection rates 60 and identify those lacking a strong FH but still requires individuals to develop cancer before 61 unaffected carriers can be identified. Forecasting models suggest addition of mainstreaming to 62 current testing rates will also necessitate ~250 years to identify the entire residual pool of 63 carriers. 4 Given the huge benefit and opportunity to prevent cancers in unaffected mutation 64 carriers, this questions the adequacy and satisfactoriness of our current clinical approach. Three cost-effectiveness analyses have evaluated population-based BRCA-testing in the Jewish-100 population. AJ-population based BRCA-testing is extremely cost-effective for both UK and US 101 health-systems and is in fact cost-saving in most scenarios.
8, 9 BRCA-mutations occur in the 102
Sephardi-Jewish population at a lower frequency of 1-in-100 than the AJ-population (1-in-40) . 103
However, this approach is extremely cost-effective in the Sephardi-population too.
10 Population-104 based BRCA-testing in the Jewish-population is one of the few interventions in medicine that can 105 save both lives and money for the health-system. Overall data support changing the paradigm to 106 population based BRCA-testing in the Jewish population. 107
Population-testing in the General-population and Panel genetic-testing 108
Adoption of NGS by genetic-testing laboratories has led to implementation of panel-genetic 109 testing for multiple cancer-susceptibility-genes (CSGs) in clinical practice. This offers the prospect 110 for population-testing of multiple CSGs. Testing for newer moderate-risk genes like 111 RAD51C/RAD51D/BRIP1 (OC-risks= 6-11%) and PALB2 (BC-risk= 44%) has now been implemented 112 and options for OC and BC risk-reduction are available for these gene-mutation carriers. RRSO is 113 cost-effective at ≥4-5% OC-risk, 11, 12 providing clinical-utility for testing for these newer moderate 114 OC-risk genes and unaffected carriers are now offered surgical prevention. Annual MRI/risk-115 reducing mastectomy is available to women at >40% risk. MLH1/MSH2/MSH6 mismatch-repair 116 (MMR) gene mutation carriers have an increased risk of colorectal-cancer (40-60%), endometrial 117 cancer (30-40%) and OC (6-14% risk). Effective options for minimising risk for them include 1-2 118 yearly colonoscopies, chemoprevention with aspirin or preventive hysterectomy and bilateral 119 salpingo-oophorectomy. All these genes can be introduced in a general-population testing panel. Women were recruited through primary-care using a web-based decision-aid along with a 125 telephone helpline. In 'The Screen Project' (http://www.thescreenproject.ca/) study general-126 population BRCA-testing is being offered to Canadian men/women >18 years through a self-paying 127 direct-to-consumer testing model. We recently showed that population-based panel-testing for 128 OC/BC gene mutations could be cost-effective for the US and UK health-systems. A population-129 based panel-testing approach is more cost-effective and can prevent thousands more cancers 130 than current clinical-criteria/FH driven BRCA or panel genetic-testing strategies. The ICER 131 (incremental cost-effectiveness ratio) were well below the £30,000/QALY (ICER= 132 £21,599.96/QALY) UK and $100,000/QALY (ICER=$54,769.78/QALY) USA willingness-to-pay 133 thresholds and sensitivity-analyses demonstrated population-testing to remain cost-effective 134 over 84% and 93% simulations for UK and US health-systems respectively. 135
Population risk-stratification 136
Newer risk-prediction models incorporating validated single-nucleotide-polymorphisms (SNPs) as 137 a polygenic-risk score along-with epidemiologic/clinical information have improved precision of 138 risk-estimation enabling population division into risk-strata, which allows targeted risk-stratified 139 screening and/or prevention for those at increased-risk. Studies for risk-stratified 140 breast/ovary/prostate cancer screening incorporating epidemiologic, mammographic-density and 141 SNP data are now being undertaken. The UK PROCAS (UKCRN-ID 8080) study has demonstrated 142 the ability for improved BC-risk prediction (adding SNPs and mammographic-density to the Tyrer-143
Cuzick model) and risk-stratified BC-screening within the NHS Breast-Screening-Programme. 13 The 144 ongoing PROMISE Feasibility-Study (ISRCTN54246466) evaluates feasibility and acceptability of 145 using a risk-prediction model (incorporating SNP-profile, panel-genetic-testing and 146 epidemiological data) for OC-risk stratification and subsequent management including 147 prevention.
14 More research/trials evaluating risk-model based stratified screening/prevention, 148 clinical effectiveness, impact, cost-effectiveness, health-behaviour, psychological/social 149 consequences are needed. 150
Summary 151
There is convincing evidence to support change in paradigm to population testing in the Jewish-152 population. Additionally there is a strong rationale for extending this to the non-Jewish general-153 population to maximise prevention. Supporting evidence for extending this to the broader 154 general-population is now emerging. Further data are needed with respect to impact of panel-155 testing in a general-population. Additional data are needed with respect to uptake of downstream 156 screening and prevention in individuals without a strong FH of cancer to re-confirm overall cost-157 effectiveness. While the majority of variants-of-uncertain-significance (VUS) identified through 158 genetic-testing are benign and will not be of any significant consequence, a small proportion of 159 class-III VUS may get re-categorised in the future into pathogenic mutations. Hence, we will also 160 need further research into impact of VUS, long-term management and monitoring of VUS and 161 development of pathways for this. This raises an urgent need for implementation studies into 162 general-population panel-testing. As further validation of absolute cancer risk models 163 incorporating epidemiologic, SNP, and other genetic/non-genetic data emerge, these can be used 164 to better stratify the population for targeted screening and prevention. This too could eventually 165 be incorporated into a future population-testing strategy. Whilst population-testing for cancer 166 genes is now reaching prime-time, this strategy could also be adopted for preventing other chronic 167 diseases in the future. Data and experience from a cancer prevention population-testing strategy 168 could also help inform approaches for prevention of other chronic diseases. The five prime causes 169 of deaths from chronic-disease are heart-disease, cancer, lung-disease, accidents and strokes. The 170 increasing prevalence of chronic-disease is the biggest challenge facing most health-systems, 171 including the NHS. In the UK these are responsible for 70% of the healthcare expenditure, 50% GP 172 appointments and 70% hospital admissions. Reducing chronic-disease burden is key for futurefinancial viability of our health system(s). Population-testing provides a new paradigm to steer 174 healthcare towards prevention for reducing the burden of cancer and potentially other chronic 175 disease. 
Disclosure of Interests

